Plasma calprotein was assessed in multiple biological treatment strategies for early rheumatoid arthritis

D. Stevens; M. Heiberg; Alex Kazemi; R Van Vollenhoven; Jon Lampa; Anna Rudin; Kristina Lend; Merete Lund Hetland; Mikkel Østergaard; Michael Nurmohamed; K Hørslev-Petersen; D.C. Nordström; B Gudbjörnsson; T Uhlig; Espen A Haavardsholm; HB Hammer

Plasma calprotein was assessed in multiple biological treatment strategies for early rheumatoid arthritis

D. Stevens, M. Heiberg, Alex Kazemi, R Van Vollenhoven, Jon Lampa, Anna Rudin, Kristina Lend, Merete Lund Hetland, Mikkel Østergaard, Michael Nurmohamed, K Hørslev-Petersen, D.C. Nordström, B Gudbjörnsson, T Uhlig, Espen A Haavardsholm, HB Hammer

Department for Rheumatology and Spine Diseases

Abstract

Background Plasma calprotectin is a sensitive inflammatory marker in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Plasma calprotectin has not previously been studied in a head-to-head trial of multiple biological mechanisms of action versus active conventional therapy (ACT) with methotrexate and prednisolone.

Original language	English
Publication date	2022
Publication status	Published - 2022
Event	EULAR 2022 - Copenhagen Duration: 1 Jun 2022 → 4 Jun 2022

Conference

Conference	EULAR 2022
City	Copenhagen
Period	01/06/2022 → 04/06/2022

Cite this

Stevens, D., Heiberg, M., Kazemi, A., Van Vollenhoven, R., Lampa, J., Rudin, A., Lend, K., Hetland, M. L., Østergaard, M., Nurmohamed, M., Hørslev-Petersen, K., Nordström, D. C., Gudbjörnsson, B., Uhlig, T., Haavardsholm, E. A., & Hammer, HB. (2022). Plasma calprotein was assessed in multiple biological treatment strategies for early rheumatoid arthritis. Annals of the Rheumatic Diseases 81 Suppl 1: 515. Abstract from EULAR 2022, Copenhagen.

Stevens, D, Heiberg, M, Kazemi, A, Van Vollenhoven, R, Lampa, J, Rudin, A, Lend, K, Hetland, ML , Østergaard, M, Nurmohamed, M, Hørslev-Petersen, K, Nordström, DC, Gudbjörnsson, B, Uhlig, T, Haavardsholm, EA & Hammer, HB 2022, 'Plasma calprotein was assessed in multiple biological treatment strategies for early rheumatoid arthritis', EULAR 2022, Copenhagen, 01/06/2022 - 04/06/2022 pp. Annals of the Rheumatic Diseases 81 Suppl 1: 515.

@conference{bccd9bada61240169c32f7b58af4e051,

title = "Plasma calprotein was assessed in multiple biological treatment strategies for early rheumatoid arthritis",

abstract = "Background Plasma calprotectin is a sensitive inflammatory marker in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Plasma calprotectin has not previously been studied in a head-to-head trial of multiple biological mechanisms of action versus active conventional therapy (ACT) with methotrexate and prednisolone.",

author = "D. Stevens and M. Heiberg and Alex Kazemi and {Van Vollenhoven}, R and Jon Lampa and Anna Rudin and Kristina Lend and Hetland, {Merete Lund} and Mikkel {\O}stergaard and Michael Nurmohamed and K H{\o}rslev-Petersen and D.C. Nordstr{\"o}m and B Gudbj{\"o}rnsson and T Uhlig and Haavardsholm, {Espen A} and HB Hammer",

note = "COPECARE; EULAR 2022 ; Conference date: 01-06-2022 Through 04-06-2022",

year = "2022",

language = "English",

pages = "Annals of the Rheumatic Diseases 81 Suppl 1: 515",

}

TY - ABST

T1 - Plasma calprotein was assessed in multiple biological treatment strategies for early rheumatoid arthritis

AU - Stevens, D.

AU - Heiberg, M.

AU - Kazemi, Alex

AU - Van Vollenhoven, R

AU - Lampa, Jon

AU - Rudin, Anna

AU - Lend, Kristina

AU - Hetland, Merete Lund

AU - Østergaard, Mikkel

AU - Nurmohamed, Michael

AU - Hørslev-Petersen, K

AU - Nordström, D.C.

AU - Gudbjörnsson, B

AU - Uhlig, T

AU - Haavardsholm, Espen A

AU - Hammer, HB

N1 - COPECARE

PY - 2022

Y1 - 2022

N2 - Background Plasma calprotectin is a sensitive inflammatory marker in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Plasma calprotectin has not previously been studied in a head-to-head trial of multiple biological mechanisms of action versus active conventional therapy (ACT) with methotrexate and prednisolone.

AB - Background Plasma calprotectin is a sensitive inflammatory marker in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Plasma calprotectin has not previously been studied in a head-to-head trial of multiple biological mechanisms of action versus active conventional therapy (ACT) with methotrexate and prednisolone.

M3 - Conference abstract for conference

SP - Annals of the Rheumatic Diseases 81 Suppl 1: 515

T2 - EULAR 2022

Y2 - 1 June 2022 through 4 June 2022

ER -